Randomised phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) therapy as a first line chemotherapy for clear cell carcinoma of the ovary.
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2018
At a glance
- Drugs Cisplatin (Primary) ; Irinotecan (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer
- Focus Registrational; Therapeutic Use
- Acronyms CCC-1; GCIG; JGOG 3017
- 07 Jan 2014 Planned number of patients changed from 662 to 652 as reported in ISRCTN: Current Controlled Trials & European Clinical Trials Database records.
- 27 Jun 2012 Additional lead trial centre identified as reported by EudraCT.
- 27 Jul 2011 Actual end date (31 Dec 2010) added as reported by as reported by ISRCTN: Current Controlled Trials.